Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
BIOLASE Inc. (NASDAQ: BIOL) shares increased 4.50 percent to close at $2.09 a share Thursday. The stock traded between $2.01 and $2.17 on volume of 1.26 million shares traded. Analysts at Sidoti have recently upgraded the company’s rating to "buy" from "neutral". Shares of BIOLASE have gained approximately 15.0 percent year-to-date.
Find out more about BIOLASE including full access to the free equity report at:
NeoStem Inc. (NASDAQ: NBS) shares increased 7.99 percent to close at $9.33 a share Thursday. The stock traded between $8.85 and $9.40 on volume of 946,803 shares traded. Analysts at MLV & Co. have recently initiated coverage on the company with a "buy" rating and a price target of $16.00.
Find out more about NeoStem including full access to the free equity report at:
Nektar Therapeutics (NASDAQ: NKTR) closed at $13.31 a share Thursday. The stock traded between $13.30 and $14.06 on volume of 1.54 million shares traded. Analysts at Cowen have recently initiated coverage on the company with an "outperform" rating and a price target of $17.00. Shares of Nektar Therapeutics have gained approximately 80.0 percent year-to-date.
Find out more about Nektar Therapeutics including full access to the free equity report at:
Nu Skin Enterprises, Inc. (NYSE: NUS) shares declined 0.47 percent to close at $93.33 a share Thursday. The stock traded between $93.01 and $94.50 on volume of 596,848 shares traded. Analysts at DA Davidson have recently downgraded the company’s rating to "neutral" from "buy". Shares of Nu Skin Enterprises have gained approximately 150.0 percent year-to-date.
Find out more about Nu Skin Enterprises including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...